Johns Hopkins Receives $20M From Roland R. Griffiths Ph.D. Professorship Fund For Psychedelic Research May 9, 2023
Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking… Feb 1, 2022
Psilocybin For Substance Use: New U.S. Gov’t Funded Study On The Way, Plus 4 PubCo’s Studying It Sep 24, 2021
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial Sep 7, 2021
Part 1 and 2: PharmaDrug CEO Daniel Cohen On Johns Hopkins University Partnership To Evaluate DMT Aug 27, 2021
PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative… Aug 25, 2021
Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School… Aug 18, 2021
